First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Oct 2016 Planned End Date changed from 1 Mar 2024 to 1 Oct 2023.
- 19 Oct 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2019.